Nintedanib Accord

Nintedanib, the active ingredient in Nintedanib Accord, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is used to treat idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and certain forms of non‑small cell lung cancer in adult patients.

GNH USA supplies Nintedanib Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nintedanib is an antifibrotic agent employed in fibrotic lung diseases and selected oncologic indications.

- Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: improves lung capacity and delays worsening. - Non‑small cell lung cancer: used in combination therapy to inhibit tumor growth.

Nintedanib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Vomiting - Decreased appetite - Abdominal pain - Headache

Serious or Rare Side Effects: - Elevated liver enzymes (ALT/AST) - Bleeding events - Cardiovascular complications (e.g., myocardial infarction) - Severe infections - Gastrointestinal perforation - Severe skin reactions (e.g., Stevens‑Johnson syndrome)

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor appropriately.

- Renal or hepatic impairment: adjust monitoring and consider dose evaluation. - Bleeding risk: avoid concomitant anticoagulants unless medically necessary. - Cardiovascular disease: monitor blood pressure and cardiac status regularly. - Pregnancy and lactation: use only if potential benefits outweigh risks. - Drug interactions: review concomitant medications for CYP3A4 substrates and inhibitors. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Nintedanib may interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - P‑glycoprotein inhibitors (e.g., verapamil): may raise plasma levels.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., rifampicin): may reduce efficacy. - Antiplatelet agents (e.g., aspirin): monitor for bleeding. - Diuretics: monitor renal function and electrolytes.